个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Yizhi[1,2] ; Li Wan[1,2] ; Yang Yihui[1,2] ; Zhang Sen[1,2] ; Yang Hong[1,2] ; Hao Yue[1,2] ; Fang Xu[1,2] ; Du Guanhua[1,2] ; Shi Jianyou[3] ; Wu Lianqiu[4] ; Wang Jinhua[1,2] ;
机构： [1]The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China [2]Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China. [3]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan, China. [4]Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
出处：
DOI： 10.1186/s12935-023-03191-3
ISSN：

关键词： Glioblastoma AAA237 BNIP3 Autophagosome–lysosome fusion

摘要：
Glioblastoma (GBM) is the most common brain tumor with the worst prognosis. Temozolomide is the only first-line drug for GBM. Unfortunately, the resistance issue is a classic problem. Therefore, it is essential to develop new drugs to treat GBM. As an oncogene, Skp2 is involved in the pathogenesis of various cancers including GBM. In this study, we investigated the anticancer effect of AAA237 on human glioblastoma cells and its underlying mechanism.CCK-8 assay was conducted to evaluate IC50 values of AAA237 at 48, and 72 h, respectively. The Cellular Thermal Shift Assay (CETSA) was employed to ascertain the status of Skp2 as an intrinsic target of AAA237 inside the cellular milieu. The EdU-DNA synthesis test, Soft-Agar assay and Matrigel assay were performed to check the suppressive effects of AAA237 on cell growth. To identify the migration and invasion ability of GBM cells, transwell assay was conducted. RT-qPCR and Western Blot were employed to verify the level of BNIP3. The mRFP-GFP-LC3 indicator system was utilized to assess alterations in autophagy flux and investigate the impact of AAA237 on the dynamic fusion process between autophagosomes and lysosomes. To investigate the effect of compound AAA237 on tumor growth in vivo, LN229 cells were injected into the brains of mice in an orthotopic model.AAA237 could inhibit the growth of GBM cells in vitro. AAA237 could bind to Skp2 and inhibit Skp2 expression and the degradation of p21 and p27. In a dose-dependent manner, AAA237 demonstrated the ability to inhibit colony formation, migration, and invasion of GBM cells. AAA237 treatment could upregulate BNIP3 as the hub gene and therefore induce BNIP3-dependent autophagy through the mTOR pathway whereas 3-MA can somewhat reverse this process. In vivo, the administration of AAA237 effectively suppressed the development of glioma tumors with no side effects.Compound AAA237, a novel Skp2 inhibitor, inhibited colony formation, migration and invasion of GBM cells in a dose-dependent manner and time-dependent manner through upregulating BNIP3 as the hub gene and induced BNIP3-dependent autophagy through the mTOR pathway therefore it might be a viable therapeutic drug for the management of GBM.© 2024. The Author(s).

基金：
This work was supported by Beijing Natural Science Foundation (7212157, China), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-029 and 2022-12M-JB-011, China). This work was also supported by National Natural Science Foundation of China (81703536, 82073311, China).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China [2]Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
通讯作者：
通讯机构： [1]The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China [2]Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
推荐引用方式(GB/T 7714)：
Zhang Yizhi,Li Wan,Yang Yihui,et al.AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway[J].CANCER CELL INTERNATIONAL.2024,24(1):69.doi:10.1186/s12935-023-03191-3.
APA：
Zhang Yizhi,Li Wan,Yang Yihui,Zhang Sen,Yang Hong...&Wang Jinhua.(2024).AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway.CANCER CELL INTERNATIONAL,24,(1)
MLA：
Zhang Yizhi,et al."AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway".CANCER CELL INTERNATIONAL 24..1(2024):69

相关文献

[1]AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway (vol 24, 69, 2024) [2]SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis [3]S670, an amide derivative of 3-O-acetyl-11-keto-β-boswellic acid, induces ferroptosis in human glioblastoma cells by generating ROS and inhibiting STX17-mediated fusion of autophagosome and lysosome [4]Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma. [5]LINC00461 Regulates the Recurrence of Large B Cell Lymphoma through the miR-411-5p/BNIP3 Pathway [6]抑制突变TP53增强胶质母细胞瘤细胞替莫唑胺敏感性及其相关机制 [7]Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development [8]Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword [9]CLINICAL TRIALS WITH DIANHYDROGALACTITOL (VAL-083) IN MGMT-UNMETHYLATED GLIOBLASTOMA [10]Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号